What are the clinical implications of the M184V reverse‑transcriptase mutation and how should antiretroviral therapy be adjusted?

M184V Reverse-Transcriptase Mutation: Clinical Implications and ART Management

Direct Answer

Despite the M184V mutation conferring high-level resistance to lamivudine and emtricitabine, integrase strand transfer inhibitor (InSTI)-based regimens containing these drugs remain effective and are recommended for both treatment-naïve and treatment-experienced patients with archived M184V mutations. 1

---

Understanding M184V: Key Clinical Characteristics

The M184V mutation is a single-base substitution in the YMDD domain of reverse transcriptase that develops rapidly during non-suppressive therapy with lamivudine (3TC) or emtricitabine (FTC). 2 This mutation:

• Confers high-level phenotypic resistance to 3TC and FTC both in vitro and in vivo 3
• Reduces viral fitness and decreases reverse transcriptase processivity 3, 4
• Increases susceptibility to tenofovir and delays emergence of thymidine analogue mutations (TAMs) 3, 4
• Persists in the HIV reservoir once selected, though it can revert relatively early after transmission compared to other resistance mutations 1

---

Treatment Approach for Virologically Suppressed Patients with Archived M184V

Recommended Regimens

For patients with viral suppression and archived M184V detected by proviral DNA genotyping, the following regimens are effective: 1

• Bictegravir/tenofovir alafenamide/emtricitabine (evidence rating: AIa) 1
• Dolutegravir plus tenofovir alafenamide/emtricitabine (evidence rating: AIa) 1
• Dolutegravir plus abacavir/lamivudine (evidence rating: AIa) 1

The key principle is that second-generation InSTIs (bictegravir, dolutegravir) have a high genetic barrier to resistance and maintain efficacy even when M184V is present, provided the InSTI component remains fully active. 1

Regimens to AVOID with M184V

Do not use 2-drug regimens containing lamivudine or emtricitabine in patients with known or archived M184V/I mutations. 1 This specifically includes:

• Dolutegravir/lamivudine dual therapy 1
• Boosted protease inhibitor plus lamivudine 1
• Dolutegravir/rilpivirine (does not contain 3TC/FTC but has lower barrier) 1

The rationale is that these regimens rely on the activity of 3TC/FTC as one of only two active agents, and M184V compromises this activity. 1

---

Treatment Approach for Virologic Failure with M184V

Initial Assessment

When M184V is detected during virologic failure:

• Confirm virologic failure (HIV RNA >200 copies/mL on two consecutive measurements) 1
• Perform resistance testing while the patient remains on the failing regimen or within 4 weeks of stopping ART 1
• Review all prior resistance test results and complete ART history 1
• Assess adherence thoroughly, including dose timing, missed doses, and drug-drug interactions 5

Switching Strategy Based on Failing Regimen

For failure of initial NNRTI-based regimen with M184V:

• Switch to dolutegravir plus 2 NRTIs (with at least 1 active NRTI determined by genotypic testing) 1
• This approach was superior to lopinavir plus NRTIs when at least one active NRTI was included 1

For failure of initial PI-based or InSTI-based therapy (without InSTI resistance):

• Use boosted PI-based or dolutegravir-based therapy with 1 or 2 fully active NRTIs 1
• The presence of M184V alone does not preclude use of tenofovir-containing regimens, as M184V increases tenofovir susceptibility 3, 4

For failure with InSTI resistance mutations present:

• Use dolutegravir 50 mg twice daily (not once daily) plus at least 1 other fully active drug 1
• Clinical data are limited for this scenario 1

---

Special Considerations and Common Pitfalls

Hepatitis B Coinfection

Never discontinue tenofovir (TDF or TAF) in patients with HIV/HBV coinfection without providing alternative HBV-active therapy, as this can cause severe hepatic reactivation. 1, 5

• Patients with HIV/HBV coinfection should receive regimens containing tenofovir plus lamivudine or emtricitabine 1
• These patients should generally not be switched to 2-drug ART regimens 1

The "Paradox" of M184V

Despite high-level resistance to 3TC/FTC, there is evidence that these drugs retain modest activity even when M184V is present, possibly due to reduced viral replication capacity. 2, 6, 3, 4 However:

• Meta-analysis shows patients with M184V have 1.87 times higher risk of virologic failure (RR 1.87; 95% CI 1.09-3.20) 7
• Viral blips are 2.26 times more common with M184V (RR 2.26; 95% CI 1.47-3.46) 7
• Viral loads during failure are similar whether M184V is present or not 6

Clinical implication: While M184V may have some beneficial effects on viral fitness, do not rely on 3TC/FTC as a fully active agent when M184V is documented. 1 Instead, use high-barrier InSTI-based regimens where the InSTI provides the primary antiviral activity.

Switching from Low-Barrier to High-Barrier Regimens

In patients with NRTI resistance mutations including M184V, switching from a boosted PI to a regimen containing drugs with low genetic barrier to resistance (e.g., NNRTI or raltegravir) is not recommended. 1 The boosted PI provides a higher barrier to resistance that should be maintained. 1

TAMs Plus M184V

Combinations of M184V with thymidine analogue mutations (TAMs) significantly reduce susceptibility to newer NRTIs including islatravir, particularly when TAM-2 mutations (D67N, K70R, T215F/Y, K219Q/E) are present. 8

• M184V plus K65R does not significantly impact susceptibility to newer agents 8
• For patients with M184V plus multiple TAMs, prioritize InSTI-based regimens where NRTI activity is less critical 1

---

Monitoring After Regimen Changes

Timing of Viral Load Assessment

• Check HIV RNA 1 month after switching regimens to ensure viral suppression is maintained 1, 5
• Monitor every 3 months for the first year after switching 5
• Once suppressed for at least 1 year with consistent adherence, monitoring can be extended to every 6 months 1

Definition of Treatment Failure

• Virologic failure requires HIV RNA >200 copies/mL confirmed on two consecutive measurements 1
• Transient blips of 20-200 copies/mL are not considered failure and should not prompt regimen changes 5
• Single viral load of 600 copies/mL should be repeated in 2-4 weeks before labeling as true failure 5

---

Algorithm for Managing M184V

Step 1: Determine Current Virologic Status

• Suppressed (<50 copies/mL) → Go to Step 2
• Failing (>200 copies/mL confirmed) → Go to Step 3

Step 2: Management of Suppressed Patients with Archived M184V

• If on effective regimen → Continue current therapy 1
• If switching needed (toxicity, simplification, cost):
  • Use bictegravir/TAF/FTC or dolutegravir + TAF/FTC or ABC/3TC 1
  • Avoid 2-drug regimens containing only 3TC/FTC 1
  • Check for HBV coinfection before removing tenofovir 1

Step 3: Management of Virologic Failure with M184V

• Obtain complete resistance profile (current + archived) 1
• Assess adherence and drug-drug interactions 5
• If failing NNRTI-based regimen:
  • Switch to dolutegravir + 2 NRTIs (≥1 active) 1
• If failing PI or InSTI (no InSTI resistance):
  • Use boosted PI or dolutegravir + 1-2 fully active NRTIs 1
• If InSTI resistance present:
  • Use dolutegravir 50 mg BID + ≥1 fully active agent 1
• If multiclass resistance (3-class):
  • Add new drug classes (fostemsavir, ibalizumab) with optimized background 1